RN3161 (LY3841136) Phase 1/2a study evaluates safety, PK/PD, and body weight effects.
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Abstract
A Phase 1/2a study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and body weight effects of RN3161 (LY3841136) as monotherapy and combined with tirzepatide.